SequelSEC

RHYTHM PHARMACEUTICALS, INC. RYTM

Pharmaceutical Preparations · CIK 0001649904 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$239.92M
Fiscal year ended 2026-06-30
Operating income
-$200.63M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

RHYTHM PHARMACEUTICALS, INC. (RYTM) reported revenue of $239.92M and net income of -$205.35M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from RHYTHM PHARMACEUTICALS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

RHYTHM PHARMACEUTICALS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$239.92M
Cost of revenue$26.39M
Gross profit$213.53M
Operating income-$200.63M
Net income-$205.35M
Research & development$173.21M
Weighted-average diluted sharesUnavailable
Pretax income-$204.28M
Income tax expense$1.07M
Diluted EPS$-3.11
Selling, general & administrative$240.94M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

RHYTHM PHARMACEUTICALS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$65.61M
Total assets$437.27M
Current assets$426.56M
Total liabilities$219.96M
Current liabilities$123.59M
Total equity incl. NCI$102.98M
Temporary (mezzanine) equity$114.32M
Inventory$30.52M
Accounts receivable$40.41M
GoodwillUnavailable
Long-term debt$93.40M
Accounts payable$16.16M

Cash flow

RHYTHM PHARMACEUTICALS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$105.35M
Capital expendituresUnavailable
Investing cash flow-$144.94M
Financing cash flow$179.79M
Net change in cash-$69.90M
Stock-based compensation$87.23M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

RHYTHM PHARMACEUTICALS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross margin89.0%
Operating margin-83.6%
FCF marginUnavailable
SBC / revenue36.4%
Current ratio3.45x
Revenue YoY growth53.5%
Net margin-85.6%
R&D / revenue72.2%
CapEx / revenueUnavailable
Long-term debt / equity0.91x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open RYTM in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-04View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-07View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.